基本信息
| 分子式 | C20H25N3O2 |
| 分子量 | 339.43 |
| MDL编码 | MFCD08062139 |
| 存储条件 | Freezer -20℃ |
产品描述
BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized. IC50 value: 5 μM[1] Target: HDAC4 In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis[2]. BML-210 inhibits the growth of NB4 cells in dose- and time-dependent manner[3].
靶点（IC50 & Targe）
HDAC
参考文献
[1]. Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40(12): 5378–5388.
[2]. Veronika V. Borutinskaite, et al. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep (2012) 39:10179–10186
[3]. Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16(8): 18252–18269.
